AU2015411258B2 - Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof - Google Patents

Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof Download PDF

Info

Publication number
AU2015411258B2
AU2015411258B2 AU2015411258A AU2015411258A AU2015411258B2 AU 2015411258 B2 AU2015411258 B2 AU 2015411258B2 AU 2015411258 A AU2015411258 A AU 2015411258A AU 2015411258 A AU2015411258 A AU 2015411258A AU 2015411258 B2 AU2015411258 B2 AU 2015411258B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
hydroxy
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015411258A
Other languages
English (en)
Other versions
AU2015411258A1 (en
Inventor
Xiaoke Guo
Tianhan HU
Yonghua LEI
Haopeng Sun
Xingsen WU
Xiaoli Xu
Qidong You
Xiaojin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of AU2015411258A1 publication Critical patent/AU2015411258A1/en
Application granted granted Critical
Publication of AU2015411258B2 publication Critical patent/AU2015411258B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015411258A 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof Ceased AU2015411258B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510648342.9 2015-10-09
CN201510648342.9A CN105130888A (zh) 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
PCT/CN2015/095728 WO2017059623A1 (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Publications (2)

Publication Number Publication Date
AU2015411258A1 AU2015411258A1 (en) 2018-05-10
AU2015411258B2 true AU2015411258B2 (en) 2020-09-17

Family

ID=54716523

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015411258A Ceased AU2015411258B2 (en) 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof

Country Status (20)

Country Link
US (2) US10889546B2 (enExample)
EP (1) EP3360862B1 (enExample)
JP (1) JP6635562B2 (enExample)
KR (1) KR20180063229A (enExample)
CN (2) CN105130888A (enExample)
AU (1) AU2015411258B2 (enExample)
BR (1) BR112018005969A2 (enExample)
CA (1) CA3000040A1 (enExample)
DK (1) DK3360862T3 (enExample)
ES (1) ES2794002T3 (enExample)
HR (1) HRP20200907T1 (enExample)
HU (1) HUE049409T2 (enExample)
LT (1) LT3360862T (enExample)
MX (1) MX379007B (enExample)
PL (1) PL3360862T3 (enExample)
PT (1) PT3360862T (enExample)
RU (1) RU2692494C1 (enExample)
SI (1) SI3360862T1 (enExample)
UA (1) UA120407C2 (enExample)
WO (1) WO2017059623A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130888A (zh) 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN107417605A (zh) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 作用于脯氨酰羟化酶的吡啶衍生化合物
WO2019080865A1 (zh) * 2017-10-25 2019-05-02 江苏恒瑞医药股份有限公司 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
CN110240562B (zh) * 2018-03-08 2022-04-12 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
MX2020012083A (es) * 2018-05-24 2021-02-09 Suzhou Suncadia Biopharmaceuticals Co Ltd Metodo de preparacion del inhibidor de alquinilpiridina prolil hidroxilasa.
CN109593084B (zh) * 2019-01-23 2021-09-28 中国药科大学 脯氨酰羟化酶小分子光敏前药及其制备方法与应用
CA3131445A1 (en) * 2019-03-04 2020-09-10 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor
US20230295110A1 (en) * 2020-08-14 2023-09-21 Akebia Therapeutics, Inc. Phd inhibitor compounds, compositions, and methods of use
CN112741834A (zh) * 2021-02-07 2021-05-04 复旦大学附属中山医院 HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途
CN116514710B (zh) * 2022-01-21 2024-07-05 中国药科大学 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410480A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2008076425A1 (en) * 2006-12-18 2008-06-26 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CL2008000066A1 (es) * 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
WO2011132633A1 (ja) * 2010-04-19 2011-10-27 第一三共株式会社 置換５－ヒドロキシピリミジン－４－カルボキサミド化合物
WO2012031298A2 (en) * 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
KR102029951B1 (ko) 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use

Also Published As

Publication number Publication date
WO2017059623A1 (zh) 2017-04-13
MX379007B (es) 2025-03-11
CN105130888A (zh) 2015-12-09
LT3360862T (lt) 2020-07-10
AU2015411258A1 (en) 2018-05-10
US20180305317A1 (en) 2018-10-25
HK1247613A1 (zh) 2018-09-28
EP3360862A4 (en) 2018-08-15
DK3360862T3 (da) 2020-06-02
PL3360862T3 (pl) 2020-09-21
CA3000040A1 (en) 2017-04-13
MX2018003832A (es) 2018-06-18
JP6635562B2 (ja) 2020-01-29
KR20180063229A (ko) 2018-06-11
JP2018529690A (ja) 2018-10-11
CN107848976B (zh) 2020-11-17
HRP20200907T1 (hr) 2020-09-04
EP3360862B1 (en) 2020-04-22
ES2794002T3 (es) 2020-11-17
BR112018005969A2 (pt) 2018-10-16
HUE049409T2 (hu) 2020-10-28
US20200407319A1 (en) 2020-12-31
SI3360862T1 (sl) 2020-08-31
US10889546B2 (en) 2021-01-12
EP3360862A1 (en) 2018-08-15
CN107848976A (zh) 2018-03-27
RU2692494C1 (ru) 2019-06-25
UA120407C2 (uk) 2019-11-25
PT3360862T (pt) 2020-05-27

Similar Documents

Publication Publication Date Title
AU2015411258B2 (en) Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
CZ291040B6 (cs) Trisubstituované fenylové deriváty a farmaceutický prostředek s jejich obsahem
CN102766099B (zh) 具有黄嘌呤氧化酶抑制活性的化合物及其盐、制备方法和用途
CA2953472C (en) Halogen-substituted heterocyclic compound salt
CN106632245B (zh) 氮取代基苯基吡唑类黄嘌呤氧化还原酶抑制剂及制备与应用
CA2517446A1 (en) 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists
TWI762634B (zh) 胺基-芳基-苯甲醯胺化合物及其使用方法
CN103524372A (zh) 一种新型组蛋白去乙酰化酶抑制剂
CN112624983B (zh) 一种含烷基结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
JPH08311011A (ja) フッ素含有ベンゾイルグアニジン類
CN106397408B (zh) 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途
JP7177577B2 (ja) 新規な化合物およびこれを含む薬学的組成物
KR20160005347A (ko) α-치환 글라이신아마이드 유도체
CN102603553B (zh) 具有协同抗真菌作用的化合物及其在药学中的用途
CN102260246B (zh) 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用
CN117126153A (zh) 一种新冠病毒抑制剂，其制备方法和其药物组合物与用途
CN109232426B (zh) 一种n-羟基-5-取代-1h-吡唑-3-甲酰胺化合物及其制备方法和用途
CN111072586B (zh) 一种n－羟基－3－取代－5－甲酰胺化合物及其制备方法和用途
HK1247613B (zh) 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
US20180064665A1 (en) N-phenyl-n'-phenoxycarbonyl-phenylsulfonhydrazide derivative and pharmaceutical composition comprising the same
CN112745284A (zh) 一种天然查尔酮衍生物及其制备方法和用途
CN115093444B (zh) 一种萘磺酰胺磷酸酯类小分子化合物及其应用
CN117731658A (zh) 一种乙脑病毒抑制剂
CN120227374A (zh) 一种rsv病毒抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired